Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 3 clinical ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

While this new treatment offers a vital lifeline, experts are simultaneously stressing the critical importance of recognising ...

This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

"Prior to the EV-302 clinical trial, the treatment of advanced bladder cancer treatment hadn't significantly changed since ...

MSD Australia & New Zealand is astonished that after eight years of dialogue and consideration, the Pharmaceutical Benefits Advisory Committee (PBAC ...

Topline results were announced from a phase 3 trial evaluating Cylembio (imsapepimut and etimupepimut, adjuvanted) in combination with pembrolizumab as a first-line treatment for advanced melanoma.

UCLA’s cancer research has been deeply impactful, with millions of people receiving drugs and therapies developed in Bruin ...

Professor Peter Johnson, NHS England’s National Clinical Director for Cancer, said: “This is one of the most hopeful advances in decades for people with bladder cancer who will now be offered a ...

Emerging treatments for low-grade serous ovarian cancer and platinum-resistant disease offer new hope, with promising data ...

I maintain a Strong Buy on Krystal Biotech, as the pause in melanoma trial enrollment is offset by promising progress in ...

First Patients Dosed on Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma Initial Data from the Expansion Study of NUC-7738 Expected in ...